Dren Bio and Sanofi Advance Collaboration on Next-Gen B-Cell Therapy
Dren Bio, a clinical-stage biotechnology company, has announced a strategic collaboration with Sanofi. This partnership focuses on developing a next-generation B-cell depleting therapy aimed at treating various autoimmune diseases.
Dren Bio and Sanofi Partnership Overview
This collaboration builds upon an existing relationship, initiated earlier this year when Sanofi acquired Dren Bio’s DR-0201 program, which is now designated SAR448501. The program has demonstrated effective B-cell depletion and shows promise for achieving sustained remission in autoimmune disease patients.
Key Details of the Collaboration
- Upfront Payment: Dren Bio will receive $100 million.
- Total Potential Value: Up to $1.7 billion in milestone payments.
- Development Responsibilities: Sanofi will manage the development, manufacturing, and commercialization post-candidate selection.
Statements from Company Officials
Alyssa Johnsen, Sanofi’s Global Therapeutic Head for Immunology and Oncology, highlighted the partnership’s aim to create cutting-edge therapies for patients with immune-mediated diseases. Amit Mehta, COO of Dren Bio, expressed enthusiasm for the collaboration, which enhances their capabilities in developing innovative therapeutics.
Financial Terms and Profit Sharing
Dren Bio has the option for a U.S. profit/loss sharing arrangement with Sanofi. If activated, Dren Bio would co-fund 40% of global development costs. In return, they would gain U.S. co-promotion rights and share profits and losses equally.
About Dren Bio
Dren Bio is a privately owned biopharmaceutical firm that specializes in pioneering first-in-class therapeutics for cancer and autoimmune diseases. Their proprietary Targeted Myeloid Engager and Phagocytosis Platform focuses on creating multispecific antibodies designed to safely eliminate disease-causing agents.
Current Research and Development
- Lead Candidate: DR-0201 (SAR448501) is undergoing evaluations in phase 1 studies.
- Second Platform Candidate: DR-0202 is in first-in-human clinical studies for solid tumors.
- Pipeline: Dren Bio continues to develop additional programs in oncology, immunology, and neurology.
This collaboration with Sanofi positions Dren Bio to accelerate the development of therapeutic options for patients facing serious autoimmune diseases. For more updates, visit El-Balad.
